🔗 Share this article

While America undertakes historic changes to its vaccine guidelines, one figure appears unexpectedly: Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by expressing skepticism about Covid vaccines during the pandemic and has zeroed in on possible fatalities following Covid vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Immunization Schedule

Public health authorities were set to announce radical changes to the childhood immunization program earlier this month, aligning the US with the Danish vaccine program, according to reports – a major change that would put the US at odds with a large portion of the world with little proof for benefit. This reveal has been pushed back until the new year.

In place of Vinay Prasad, Høeg is scheduled to present at the meeting. She was recently named temporary leader of the FDA’s CDER, the fifth person to head the office this calendar year.

A New Direction at the Agency

Høeg's temporary position could signify a closer partnership between the drug and biologics branches as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a greater focus upon dismantling long-standing vaccines at the FDA.

The new acting director has often pushed for halting specific pediatric shot schedules in the US to become more like the Danish model, a nation with comprehensive healthcare and a citizenry about the size of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccination policy – traditionally the domain of Prasad, director of the FDA’s CBER – rather than pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has no obvious experience in pharmaceutical research, oversight or management, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the agency head and CBER since earlier this year.

“She appears not to have the requisite experience” for running the CDER, stated a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She has no expertise in leading a major agency. She lacks background in pharmaceutical oversight.”

Past directors of CBER would “be deeply familiar with laws and regulations and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that former directors who headed the center have had.”

This division has an vast portfolio at the FDA, Woodcock emphasized.

“The public just zeroes in on the novel medication approvals, but the off-patent medication office approves a multitude of generic medications. There’s a biosimilars division, non-prescription drug unit and so forth, and all of those must be supervised,” Dr. Woodcock said. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

There is also, a major administrative aspect to the position, which oversees over 5,000 personnel. “It’s a enormous leadership role, if you execute it properly,” she concluded.

Response and Contentious Initiatives

Regarding inquiries about Dr. Høeg's credentials and whether this appointment represents more teamwork among agency officials on vaccines, a representative stated that the “questions rely on flawed presumptions”.

“This background is consistent with the functions of her position,” the representative said, citing the time Dr. Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg inherits the agency head's new priority voucher program, a contentious rapid medication authorization process that apparently troubled her preceding directors. “How are these medications being selected for this expedited pathway? Who is making the choices?” Dr. Howard questioned. “There’s a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he remarked, “the Food and Drug Administration looks to be trending towards more relaxed rules of most medications, aside from vaccines.”

Public Track Record on Immunizations

With vaccines, Dr. Høeg has a more established, if problematic, history, some experts said. She published a research paper using non-validated volunteer-provided data to estimate the rate of myocarditis after COVID-19 vaccination. She advised the Florida top health official Dr. Joseph Ladapo, who was said to have altered data to indicate Covid vaccinations are riskier than they are.

Included in her “policy goals” for the new federal leadership included changing regulations for novel immunizations and ending “optional” vaccines, she remarked post-election on a podcast. At the FDA, Dr. Høeg has according to sources floated the idea of excluding teenage boys from obtaining Covid vaccines.

“She’s an complete ideologue who starts off with her preconceived notions and tailors the evidence to fit the evidence in a extremely disingenuous, untruthful way,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg aligned with fellow skeptics, {like|